Rigel Pharmaceuticals(RIGL)
SOUTH SAN FRANCISCO, CAPharmaceutical
Focus: Rigel is a mid-cap specialty pharma company focused on small-molecule therapeutics in neurology and hematology/oncology. The company markets three peak-stage products with TAVALISSE (fostamatinib) generating 85% of revenue.
Profile data last refreshed 7h ago · AI intelligence enriched 3w ago
Funding Stage
PUBLIC
Open Jobs
0
About Rigel Pharmaceuticals
AI assessmentNot HiringNo open roles listed right now. Follow Rigel Pharmaceuticals to get notified when they start hiring — the background below is worth knowing for when they do.
Generated by Claude from Rigel Pharmaceuticals's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Data completeness
6/9 — Partial
Company HealthStrong
Pipeline
Late-stage
6 Phase 3+
LOE Risk
Protected
No near-term cliffs
Hiring
0 open
Revenue
$117M
Key Products
$40M Part DDeclining
Peak
Help build intelligence for Rigel Pharmaceuticals
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.